Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 1/20 | 0.54 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.54 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.54 |
| ▸ | NSD2 | O96028 | 1/20 | 0.51 |
| ▸ | CTSK | P43235 | 2/20 | 0.51 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.50 |
| ▸ | SUV39H2 | Q9H5I1 | 4/20 | 0.49 |
| ▸ | AR | P10275 | 4/20 | 0.48 |
| ▸ | CKS1B | P61024 | 1/20 | 0.47 |
| ▸ | SKP1 | P63208 | 1/20 | 0.47 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.47 |
| ▸ | JAK3 | P52333 | 1/20 | 0.46 |
| ▸ | BTK | Q06187 | 1/20 | 0.46 |
| ▸ | BRD4 | O60885 | 2/20 | 0.45 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.44 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12835989 | 0.88 | PIM1 (0.58) | PIM1PIM3PIM2CTSKKCNA3 | |
| SCHEMBL12836009 | 0.86 | PIM1 (0.50) | PIM1PIM3PIM2CTSKKCNA3 | |
| SCHEMBL12835665 | 0.85 | CTSK (0.53) | PIM1PIM3PIM2CTSKKCNA3 | |
| SCHEMBL3609235 | 0.85 | AR (0.51) | AR | |
| SCHEMBL2464322 | 0.85 | KCNA3 (0.57) | PIM1PIM3PIM2NSD2CTSK | |
| SCHEMBL12836043 | 0.84 | CTSK (0.52) | PIM1PIM3PIM2CTSKSUV39H2 | |
| SCHEMBL12836076 | 0.84 | BTK (0.53) | PIM1PIM3PIM2NSD2CTSK | |
| SCHEMBL12835680 | 0.84 | SUV39H2 (0.53) | PIM1PIM3PIM2CTSKSUV39H2 | |
| SCHEMBL12835967 | 0.83 | SUV39H2 (0.49) | PIM1PIM3PIM2NSD2CTSK | |
| SCHEMBL12836025 | 0.83 | CTSK (0.50) | PIM1PIM3PIM2CTSKKCNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1553074-B1 | FUSED BENZENE DERIVATIVE AND USE | TAKEDA PHARMACEUTICAL (JP) | 2014-06-18 | — | — | EP | disclosed |
| US-7649001-B2 | Fused benzene derivative and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-01-19 | — | — | US | disclosed |
| US-20090042857-A1 | Novel Pharmaceutical | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-02-12 | — | — | US | disclosed |
| EP-1987827-A1 | NOVEL PHARMACEUTICAL | Takeda Pharmaceutical Company Limited (JP) | 2008-11-05 | — | — | EP | disclosed |
| US-20060106067-A1 | Fused benzene derivative and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-05-18 | — | — | US | disclosed |
| EP-1553074-A1 | FUSED BENZENE DERIVATIVE AND USE | Takeda Pharmaceutical Company Limited (JP) | 2005-07-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060106067-A1 | Fused benzene derivative and use | AR, NR5A1, CBR3 | PIM1 3907/4885PIM3 3328/4885PIM2 3876/4885 |
| US-20090042857-A1 | Novel Pharmaceutical | AR, NR5A1, NR5A2 | PIM1 3838/4885PIM3 3392/4885PIM2 4157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.